Loading clinical trials...
Loading clinical trials...
In this study, the safety and effectiveness of the Oculeve Intranasal Lacrimal Neurostimulator after 180 days of use in participants with aqueous tear deficiency will be evaluated.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Oculeve, Inc.
NCT07412860 · Dry Eye Syndromes, Dry Eye Disease (DED)
NCT03135327 · Multiple Sclerosis, Dry Eye Syndromes, and more
NCT02585414 · Dry Eye Syndromes
NCT06848829 · Dry Eye Syndromes
NCT06220474 · Dry Eye Syndromes, Meibomian Gland Dysfunction
Cornea & Cataract Consultants of Arizona
Phoenix, Arizona
Andover Eye Associates
Andover, Massachusetts
Total Eye Care
Memphis, Tennessee
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions